Oxytocin - Oxytone Bioscience

Drug Profile

Oxytocin - Oxytone Bioscience

Alternative Names: 14C-labelled oxytocin; Orally disintegrating oxytocin - Oxytone Bioscience

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxytone Bioscience
  • Class Hormones; Oxytocics
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Labour disorders

Most Recent Events

  • 06 Apr 2018 Oxytone withdraws a phase I trial in Labour disorders (In volunteers) prior to enrolment, due to financial issues (NCT02911480)
  • 03 Apr 2018 Phase-I clinical trials in Labour disorders (In volunteers) in Sweden (IV) (PO) (NCT02908126)
  • 12 Apr 2017 Oxytone plans a phase I trial for Labour disorders (In volunteers) (NCT02911480)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top